Type 2 Diabetes Clinical Trial
Official title:
The Effect of Motivational Interviewing With Focus on Diet and Weight Gain on Prevention of Excessive Fetal Growth in Pregnant Women With Type 2 Diabetes
NCT number | NCT02883127 |
Other study ID # | H-15009413 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | August 1, 2015 |
Est. completion date | October 1, 2019 |
Verified date | May 2021 |
Source | Rigshospitalet, Denmark |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The primary goal of this case control study is to investigate the effect of implementation of motivational interviewing with focus on diet and weight gain in addition to the routine treatment on prevention of excessive gestational weight gain and fetal growth in pregnant women with type 2 diabetes. Design: Prospective cohort study where an unselected cohort of all pregnant women with type 2 diabetes are offered intervention with motivational interviewing in addition to routine treatment in the period 2015-2017. For comparison a historical cohort (2013-2015) treated with routine treatment only will be studied. With an inclusion period of 2 years, each cohort is expected to include 150 participants. The women in the study group will receive one-to-one coaching based on the principles of motivational interviewing, every second week throughout the pregnancy. Both cohorts receive the same routine care for pregnant women with type 2 diabetes. An appropriate GWG is targeted. Primary outcome measures are maternal gestational weight gain and the infants Large for Gestational Age.
Status | Completed |
Enrollment | 189 |
Est. completion date | October 1, 2019 |
Est. primary completion date | February 28, 2018 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - All pregnant women with type 2 diabetes and older than 18 years referred to Center for Pregnant Women with Diabetes, Rigshospitalet or Department of Obstetrics and Endocrinology, Odense University Hospital with a live singleton pregnancy will be included in the study group. All pregnant women with type 2 diabetes in the period August 2013 - August 2015 who received routine care only at the same centers will be included in the control group.´ - Referral before 20 gestational weeks. Women with newly diagnosed type 2 diabetes before week 20 may be included (HbA1c = 48 mmol/mol). - Able to read and understand the patient information sheet and to converse with the lifestyle coach in Danish. Exclusion Criteria: - Previous bariatric surgery i.e. ether previous gastric bypass or gastric banding operation. - Women diagnosed with severe diseases which possibly could bias the weight gain or pregnancy outcome on the decision of the principal investigators. |
Country | Name | City | State |
---|---|---|---|
Denmark | Center for Pregnant Women with Diabetes | Copenhagen | Østerbro |
Lead Sponsor | Collaborator |
---|---|
Rigshospitalet, Denmark | Odense University Hospital |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Gestational weight gain | The difference between weight measured at gestational week 35-37 and weight from preconception (self-reported) or if not available, at first pregnancy visit within first trimester. | 2 years and 9 months | |
Primary | Large for gestational age | Birth weight = 90th percentile, adjusted for gestational age and sex. Z-score =1.28. | 2 years and 9 months | |
Primary | HbA1c | noted 3 times during pregnancy | 2 years and 9 months | |
Secondary | Pre-eclampsia: | De novo hypertension >140/90 mmHg after 20 weeks and the coexistence of one or more of the following new onset conditions:
Proteinuria (spot urine protein/creatinine ratio = 30 mg/mmol (0.3 mg/mg) or = 300 mg/day or at least 1 g/L ('2+') on dipstick testing or albumin excretion (UAE) = 190 mg/day or Albumin Creatine Ratio (UACR) = 190 mg/g creatinine). Other maternal organ dysfunction: renal insufficiency (creatinine =90 umol/L) liver involvement (elevated transaminases; at least twice upper limit of normal and right upper quadrant or epigastric abdominal pain Neurological complications (including eclampsia, altered mental status, blindness, stroke, hyperreflexia when accompanied by clonus, severe headaches when accompanied by hyperreflexia and persistent visual scotomata) Haematological complications (thrombocytopenia: platelet count <150,000/dl, disseminated intravascular coagulation and haemolysis) Uteroplacental dysfunction and fetal growth restriction I |
2 years and 9 months | |
Secondary | Preterm delivery | Birth before 37 completed gestational weeks (259 days). | 2 years and 9 months | |
Secondary | Caesarean section: | Emergency: The procedure is made within 8 hours after clinical decision.
Elective: Planned C-section. |
2 years and 9 months | |
Secondary | Duration from induction of labor to delivery | The time in hours from onset of intervention (example Misoprostol, Cervical Ripening Balloon, amniotomy) to delivery. | 2 years and 9 months | |
Secondary | Duration of active labor | Regular labor with contractions = 5 minutes interval and orificium is = 4 cm dilated without persistant collum. The appraisal will be made by local midwives. | 2 years and 9 months | |
Secondary | Shoulder dystocia | Shoulder dystocia is a situation when the fetus's shoulders cannot pass below the mother's pubic symphysis after delivery of the head and specific obstetric maneuvers, usually Rubin´s or/and Wood´s maneuvers, are necessary to deliver the baby. Presence of fetal asphyxia, nerve lesions and fractures will be noted. | 2 years and 9 months | |
Secondary | Degree of rupture | degree: laceration is limited to the fourchette and superficial perineal skin or vaginal mucosa.
degree: laceration extends to perineal muscles and fascia. degree: laceration extends to the anal sphincter. degree: laceration extends to the rectal mucosa. |
2 years and 9 months | |
Secondary | Birth weight z-score | Number of standard deviations from the mean of a Nordic population, adjusted for gestational age and sex. | 2 years and 9 months | |
Secondary | Small for Gestational Age (SGA) | Birth weight = 10th percentile, adjusted for gestational age and sex. Z-score = 1.28. | 2 years and 9 months | |
Secondary | Ponderal index | Weight divided by the third power of body length. | 2 years and 9 months | |
Secondary | International neonatal hypoglycemia: | Neonatal hypoglycemia defined as a plasma glucose value below 2.2 mmol/L, measured within 4 hours of life. | 2 years and 9 months | |
Secondary | Danish Neonatal hypoglycemia | Neonatal hypoglycemia defined as a plasma glucose value below 2.5 mmol/L, measured within 4 hours of life. | 2 years and 9 months | |
Secondary | Jaundice | Need for phototherapy or exchange transfusion | 2 years and 9 months | |
Secondary | Transient tachypnea of the newborn (TTN) | A need for Continuous Positive Airway Pressure (CPAP) for more than 60 minutes. | 2 years and 9 months | |
Secondary | Major congenital malformations | Those leading to death, causing a substantial future handicap or requiring surgery. | 3 years and 9 months | |
Secondary | Perinatal mortality | Perinatal death includes infant deaths that occur at less than 28 days of age and fetal deaths with a stated or presumed period of gestation of 20 weeks or more. | 2 years and 9 months | |
Secondary | Perinatal morbidity | The occurrence of at least one of the following complications: neonatal hypoglycemia, jaundice, TTN, congenital malformations, perinatal mortality or admission to neonatal special care unit (NSCU). | 2 years and 9 months | |
Secondary | Apgar score | The examination immediately after birth on five criteria on a three point scale (0,1 and 2), with a maximum points of 10 after 5 minutes. | 2 years and 9 months | |
Secondary | Body mass index (BMI) | Underweight: < 18.5 kg/m2
Normal weight: 18.5-24.9 kg/m2 Overweight: 25.0-29.9 kg/m2 Obese: = 30.0 kg/m2 |
2 years | |
Secondary | Hypoglycaemia | Mild: Events with symptoms familiar to the patient as hypoglycemia and managed by the patient.
Severe: Events with symptoms of hypoglycemia requiring help from another person to actively administer oral carbohydrate or injection of glucagon or glucose in order to restore the blood glucose level. |
2 years | |
Secondary | Kidney involvement | Microalbuminuria or diabetic nephropathy. | 2 years | |
Secondary | Diabetic nephropathy | U-albumine >300 mg/day or ACR, >300 mg/g of creatinine or >34 mg/mmol of creatinine | 2 years | |
Secondary | Microalbuminuria | 30-300 mg/day albumin or ACR, 30-300 mg/g of creatinine or 3.4-34 mg/mmol of creatinine. | 2 years | |
Secondary | Diabetic retinopathy | Presence of any diabetic retinopathy at first visit. | 2 years | |
Secondary | Ethnicity | -Nordic Caucasian: When pregnant woman originates from Northern Europe. | 2 years | |
Secondary | Maternal waist circumference | measured at the level midway between the lowest ribcage and the iliac crest | 2 years | |
Secondary | Maternal neck circumference | Measured between midcervical spine and mid-anterio neck | 2 years | |
Secondary | Maternal ankle circumference | measured 5 cm above the malleolus | 2 years | |
Secondary | Infants weight, length, and head circumference | 2 years and 9 months | ||
Secondary | Infants abdominal circumference, upper- and lower arm and upper- and lower leg circumference | 2 years and 9 months | ||
Secondary | Infants skin fold measurements of triceps, quadriceps, subscapular and suprailiac region | 2 years and 9 months | ||
Secondary | Maternal lipid profile at first visit | 2 years | ||
Secondary | Cord blood pH | 2 years and 9 months | ||
Secondary | Post-partum weight retention | 3 years and 9 months | ||
Secondary | Baby´s weight at 1 year | 3 years and 9 months | ||
Secondary | Baby´s morbidity the first year | 3 years and 9 months | ||
Secondary | Maternal health during pregnancy | HADS questionnaire | 2 years | |
Secondary | Maternal after measurement of subcutaneous skin folds (biceps, triceps, suprailiac and subscapular). | Measured with a Harpenden caliper according to the method described by Durnin and Womersly | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |